The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs

Life Sciences

Volumn 60, Issue 18, 1997, Pages 1553-1561

  Phebus, Lee A ^a   Johnson, Kirk W ^a   Stengel, Peter W ^a   Lobb, Karen L ^a   Nixon, James A ^a   Hipskind, Philip A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

LY303870; migraine; neurogenic dural inflammation; NK 1 receptor; substance P

Indexed keywords

LANEPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; PLASMA PROTEIN; SUBSTANCE P; SUMATRIPTAN; SUMATRIPTAN SUCCINATE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DURA MATER; ELECTROSTIMULATION; ENANTIOMER; EXTRAVASATION; GUINEA PIG; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIGRAINE; NEUROGENIC INFLAMMATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RECEPTOR AFFINITY; TRIGEMINUS GANGLION;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DURA MATER; ELECTRIC STIMULATION; GUINEA PIGS; INDOLES; MALE; MIGRAINE DISORDERS; PIPERIDINES; RECEPTORS, NEUROKININ-1; STEREOISOMERISM; SUMATRIPTAN;

ANIMALIA; CAVIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 0030935008     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00121-5     Document Type: Article

References (21)

1. D. REGOLI, G. DRAPEAU, S. DION and P. D'ORLEANS-JUSTE, Pharmacology 38 1-15 (1989).
2. S.L. SHEPHEARD, D.J. WILLIAMSON, J. WILLIAMS, R.G. HILL and R.J. HARGREAVES, Neuropharmacology 34 255-61 (1995).
3. M. MAYBERG, R.S. LANGER, N.T. ZERVAS and M.A. MOSKOWITZ, Science 213 228-30 (1981).
4. M.A. MOSKOWITZ, J. REINHARD, Jr., J. ROMERO, E. MELAMED and D.J. PETTIBONE, Lancet 2 883-5 (1979).
5. L. JACQUES, R. COUTURE, G. DRAPEAU and D. REGOLI, Naunyn Schmiedebergs Arch Pharmacol 340 170-9 (1989).
6. R. COUTURE and A.C. CUELLO, J Physiol 346 273-85 (1984).
7. S. MARKOWITZ, K. SAITO and M.A. MOSKOWITZ, J Neurosci 7 4129-36 (1987).
8. S.M. MOUSSAOUI, L. PHILIPPE, N. LE PRADO and C. GARRET, Eur. J. Pharmacol. 238 421-24 (1993).
9. S.L. SHEPHEARD, D.J. WILLIAMSON, R.G. HILL and R.J. HARGREAVES, Br J Pharmacol 108 11-2 (1993).
10. P.A. HIPSKIND, J.J. HOWBERT, R.F. BRUNS, S.S. CHO, T.A. CROWELL, M.M. FOREMAN, D.R. GEHLERT, S. IYENGAR, K.W. JOHNSON, J.H. KRUSHINSKI, D.L. LI, K.L. LOBB, N.R. MASON, B.S. MUEHL, J.A. NIXON, L.A. PHEBUS, D. REGOLI, R.M. SIMMONS, P.G. THRELKELD, D.C. WATERS and B.D. GITTER, J Med Chem 39 736-48 (1996).
11. B.D. GITTER, R.F. BRUNS, J.J. HOWBERT, D.C. WATERS, P.G. THRELKELD, L.M. COX, J.A. NIXON, K.L. LOBB, N.R. MASON, P.W. STENGEL, S.L. COCKERHAM, S.A. SILBAUGH, D.R. GEHLERT, D.A. SCHOBER, S. IYENGAR, D.O. CALLIGARO, D. REGOLI and P.A. HIPSKIND, J Pharmacol Exp Ther 275 737-44 (1995).
12. W.S. LEE, S.M. MOUSSAOUI and M.A. Moskowitz, Br J Pharmacol 112 920-4 (1994).
13. T.T. MERCER, M.I. TILLERY and H.Y. CHOW, Am Ind Hyg Assoc J 29 66-78 (1968).
14. T.T. MERCER, M.I. TILLERY and G.J. NEWTON, J. Aerosol. Sci. 1 9-15 (1970).
15. A.C. GUYTON, Am. J. Physiol. 150 70-7 (1947).
16. Z. HUANG, B. BYUN, T. MATSUBARA and M.A. MOSKOWITZ, Br J Pharmacol 108 331-5 (1993).
17. W.S. LEE and M.A. MOSKOWITZ, Brain Res 626 303-5 (1993).
18. B.D. GITTER, D.C. WATERS, R.F. BRUNS, N.R. MASON, J.A. NIXON and J.J. HOWBERT, Eur J Pharmacol 197 237-8 (1991).
19. C.M. DIXON, D.A. SAYNOR, P.D. ANDREW, J. OXFORD, A. BRADBURY and M.H. TARBIT, Drug Metab Dispos 21 761-9 (1993).
20. M.G. BUZZI and M.A. MOSKOWITZ, Br J Pharmacol 99 202-6 (1990).
21. M.G. BUZZI, W.B. CARTER, T. SHIMIZU, H.d. HEATH and M.A. MOSKOWITZ, Lancet 335 822-3 (1990).